An official website of the United States government
Home
Name
Ziihera
Alternate Names
Zanidatamab
Zanidatamab-hrii
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
None
NSC Number
None
Primary Site
Bile ducts, Gall bladder
Histology
None
Remarks
November 22, 2024 FDA accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer, as detected by an FDA-approved test.
Coding
This drug should be coded
